The FDA has granted Fast Track designation to the combination of SonALAsense’s proprietary drug and Insightec’s focused ultrasound device for the treatment of pediatric brain tumors.
The Fast Track program facilitates the development and expedited review of drugs to fill an unmet medical need.
The American Medical Association has issued a category I CPT® code for treating essential tremor (ET) and Parkinson’s disease with Insightec’s Exablate Neuro focused ultrasound device.
The company also announced reimbursement news for patients with ET in Australia.
The UK Focused Ultrasound Foundation (UKFUSF), in collaboration with prostate cancer charity Prost8, has funded a new prostate cancer focused ultrasound treatment site at Royal United Hospitals Bath.
The new unit is an example of how donor funding to UKFUSF is being used to bridge the gap between laboratory research and widespread patient treatment in the UK.
“Whenever I was treated by focused ultrasound, I was peaceful due to no pain, so my life became stable. I am so grateful for the opportunity to get treated as part of this clinical trial.”